Policy Matters to #SmallBiz and Entrepreneurship. Who better to lead a panel on this with ⁦Senate Small Biz⁩ ⁦U.S. Senate Small Biz & Entrepreneurship Committee⁩ staff and our UK 🇬🇧 counterparts representing entrepreneurs than ⁦John Stanford⁩ ⁦Small Business Roundtable⁩. 🇺🇸🇬🇧

In the world of Making Medicine, every day should be #WorldIPDay. Intellectual property drives innovation and more importantly creates better outcomes for patients. Learn more about how we've been celebrating IP from the beginning -> incubatecoalition.org/incubate-celeb…

Nature is awesome

Given what we *know* about size of rebates in this space -- it's irresponsible to write articles or tables that lead with list price and put in a caveat that there "may" be rebates. Even having a table with only list prices is writing click bait and not careful analysis.

Would love to been on the POLITICO editorial team that picked each pic. Scott and Haley - happy!

Advocacy at its tastiest.

These zebras clearly live at the National Zoo. #BroncosCountry

Between #hatgate and #alarmgate hard to even notice we might avoid #shutdown

Dave Killoran Future lawyer dinner parties will suck as they will not know how to strategically arrange guest seats.

Just thinking of 8th grade civics teachers who told the class "we'll watch CSPAN today" and got WWE.

FTC vs Sanofi/Maze: very bad precedent for gov't overreach. And bad in general for patients in all disease areas FTC continues to create friction in the deal mkt that is so vital to our collaborative biotech ecosystem reliant on external innovation globenewswire.com/news-release/2…

This is a “classic example of a market failure, with little to no incentive to invest in #AMR versus other promising therapeutics,” John Stanford explains. biospace.com/article/why-is…

#EX24Canada has kicked off in #Toronto with opening remarks from SBR Co-Executive Director John Stanford. Today's agenda is stacked with North America's leading voices in #smallbiz. #entrepreneurshipexchange

Japan can be a biotech powerhouse. That's what we're working on.

Good things come in small molecules. Fix the #pillpenalty. Happy Valentine’s Day! ❤️ 💊

"What are we going to do from a national security perspective when China has the cure for diabetes?" John Stanford at last week's Punchbowl News fireside chat, stressing that when the U.S. falls behind in biotech, it poses a risk to our medical supply chains.

"Startups are being forced to make hard choices: shelve promising programs, pull back on trials or pivot away from entire classes of cutting-edge and potentially life-saving drugs." John Stanford in @BioSpace on why Congress must pass the EPIC Act. buff.ly/kHCSGZU

Last week, John Stanford joined Punchbowl News for a fireside chat on the future of medicine, stressing the need to sustain U.S. leadership in life sciences and boost investment in small biotechs developing lifesaving treatments.

"We want foreign investors coming to U.S.-based companies to develop drugs for the world." John Stanford spoke with FierceBiotech at this year's BIO Convention about supporting a robust U.S. life sciences sector.

Small molecule companies are "not the cool kid in the class anymore," John Stanford told PharmaVoice. He outlines Incubate's survey findings on how the IRA, tariffs, and NIH cuts are shaking biotech CEOs confidence -- and what that means for Washington. buff.ly/sARIRwh